cf sale million confid triplerx approv
total cf sale million beat street consensu million symdeko
launch symkevi germani contribut beat new reimburs
agreement led orkambi growth vertex rais cf sale guidanc
forecast billion year vertex file nda triplerx elexacaftor
symdeko approv earli treat homozyg unserv het/
min cf patient provid next leg growth billion vertex recent
expand allianc crispr develop gene edit medicin dmd
myoton dystrophi crispr vertex alreadi partner beta
thalassemia patient transfus independ sinc engraft month
reiter overweight rate increas price target
roll forward discount period
cf total cf sale million beat estim street
consensu symdeko/symkevi sale million drove beat continu
uptak germani despit expect symdeko cannib orkambi
sale grew million due label reimburs expans vertex increas
cf sale guidanc billion forecast billion
confid triplerx approv earli vertex file nda
prioriti review triplerx consist next-gen corrector elexacaftor
symdeko tezacaftor/ivacaftor therapi estim address
cf patient world-wide includ current treat homozyg patient
importantli het/min cf patient exist therapi highli confid
triplerx european approv next year rapid uptak among
 het/min patient forecast triplerx sale billion total cf sale
billion
lead gene edit vertex crispr partner first
beta thal patient treat transfus free sinc engraft
month first scd patient treat look data
serv import valu driver vertex recent expand allianc
crispr develop gene edit medicin treat dmd vertex develop
commerci dmd compani share cost crispr
retain option co-develop/co-commerci time ind file
acquisit exon vertex lead dmd gene edit player
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
price close juli
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
reiter overweight rate increas price target
roll forward discount period appli price-to-earnings multipl
non-gaap dilut ep prior appli multipl non-gaap
dilut ep discount back non-gaap dilut
ep estim essenti in-lin prior estim base higher total
cf sale billion higher oper expens view multipl appropri
base high confid triplerx phase data quarter subsequ acceler
revenu earn gorwth
rate crispr juli close overweight price target base proj
ev billion net cash
risk technolog unproven may fail man crispr involv patent
litig could advers effect compani abil conduct busi compani
page
good sold
thousand except per share data
net incom loss attribut allio
compani report piper jaffray co analysi
current disclosur inform compani found
